Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy Targeting CD22 in Treating Patients With B Cell Malignancies

NCT03262298 is registered in ClinicalTrials.gov with Affiliated Hospital to Academy of Military Medical Sciences as lead sponsor.

NCT NCT03262298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03262298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy Targeting CD22 in Treating Patients With B Cell Malignancies
Lead sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 20, 2017
Completion date
August 20, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma